Mehta Shivan J, Volpp Kevin G, Asch David A, Goldberg Lee R, Russell Louise B, Norton Laurie A, Iannotte Lauren G, Troxel Andrea B
Departments of Medicine and Health Policy and Medical Ethics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA (S.J.M., K.G.V., D.A.A., L.R.G., L.B.R., L.A.N., L.G.I.).
The Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA (S.J.M., K.G.V., D.A.A.).
Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005126. doi: 10.1161/CIRCOUTCOMES.118.005126.
Congestive heart failure is a major cause of morbidity, mortality, and cost. Disease management programs have shown promise but lack firm evidence of effectiveness and scalability. We describe the motivation, design, and planned analyses of EMPOWER (Electronic Monitoring of Patients Offers Ways to Enhance Recovery), a randomized clinical trial of an innovative intervention incorporating behavioral economic principles with remote monitoring technology embedded within a healthcare system.
EMPOWER is an ongoing, pragmatic, randomized clinical trial comparing usual care to an automated hovering intervention that includes patient-level incentives for daily weight monitoring and diuretic adherence combined with automated feedback into the clinical care pathway, enabling real-time response to concerning clinical symptoms. Identification of eligible patients began in May 2016, and implementation of the intervention is feasible. Trial processes are embedded into existing clinical pathways. The primary outcome is time to readmission for any cause. Cost-effectiveness analyses are planned to evaluate the healthcare costs and health outcomes of the approach.
The EMPOWER trial incorporates leading-edge approaches in human motivation, derived from behavioral economics, with contemporary technology to provide scale and exception handling at low cost. The trial is also implemented within the naturalized environment of a health system, as much as possible taking advantage of the existing journeys of patients and workflows of clinicians. A goal of this pragmatic design is to limit resource utilization and also to test an intervention that would need minimal modification to be translated from research into a new way of practice.
URL: https://www.clinicaltrials.gov . Unique identifier: NCT02708654.
充血性心力衰竭是发病、死亡和成本的主要原因。疾病管理项目已显示出前景,但缺乏有效性和可扩展性的确凿证据。我们描述了EMPOWER(患者电子监测促进康复)的动机、设计和计划分析,这是一项随机临床试验,该创新干预措施将行为经济学原理与嵌入医疗系统的远程监测技术相结合。
EMPOWER是一项正在进行的、务实的随机临床试验,将常规护理与自动 hovering 干预进行比较,该干预包括针对每日体重监测和利尿剂依从性的患者层面激励措施,并将自动反馈纳入临床护理路径,从而能够对相关临床症状进行实时响应。符合条件的患者识别工作于2016年5月开始,干预措施的实施是可行的。试验流程已嵌入现有的临床路径。主要结局是因任何原因再次入院的时间。计划进行成本效益分析以评估该方法的医疗成本和健康结局。
EMPOWER试验将源自行为经济学的人类动机方面的前沿方法与当代技术相结合,以低成本提供规模和异常处理能力。该试验也是在医疗系统的自然环境中实施的,尽可能利用患者的现有就医过程和临床医生的工作流程。这种务实设计的一个目标是限制资源利用,并测试一种从研究转化为新的实践方式时只需进行最小修改的干预措施。
网址:https://www.clinicaltrials.gov 。唯一标识符:NCT02708654。